Allergan-tribe ruling raises questions over immunity at PTAB: lawyers

The US Court of Appeals for the Federal Circuit’s ruling that tribal sovereign immunity doesn’t apply in inter partes review (IPR) proceedings has sparked questions over state protections at the Patent Trial and Appeal Board (PTAB).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Tribal immunity not applicable in IPR, says Fed Circuit

20 July 2018 Allergan and the Saint Regis Mohawk Tribe suffered a blow today as the US Court of Appeals for the Federal Circuit affirmed a decision rejecting use of tribal sovereign immunity in the inter partes review.

Americas

Mohawk tribe and Allergan seek en banc hearing in Restasis case

21 August 2018 Allergan and the Saint Regis Mohawk Tribe asked the full US Court of Appeals for the Federal Circuit on Friday to review an earlier decision that rejected use of tribal sovereign immunity in the inter partes review.

Americas

Federal Circuit refuses tribal immunity rehearing

23 October 2018 In a blow to Allergan and the Saint Regis Mohawk Tribe, the US Court of Appeals for the Federal Circuit yesterday refused to reconsider an earlier decision that rejected use of tribal sovereign immunity in inter partes reviews.